NV-TOMTOM
TomTom (TOM2 ) is announcing the launch of the new TomTom Sports app today, bringing not just activity data, but insights and motivation, to millions of users.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170105005171/en/
The new TomTom Sports app, co-created with athletes and fitness app users, gets people going by introducing motivational messages, activity trends and comparisons, performance stats down to the second, rich social sharing functions, presented in an attractive and friendly design.
“We have been creating wearables since 2009, and since then much has changed. The large amounts of data people now have access to, is overwhelming. What people really need in that moment where excuses beat conviction, is motivation and a better understanding of what works for them. With our new TomTom Sports app we turn data into insights to do just that. This launch marks the beginning of what will be a hugely exciting year for our brand in the world of sports.” Says Corinne Vigreux, Co-Founder and Managing Director TomTom Consumer.
The TomTom Sports app provides a single place to track up to 12 different activity types ranging from running, cycling and swimming to skiing, trail running and hiking.
The app can show your latest efforts and achievements – such as changes in body composition1 and resting heart rate1 - at a glance. It also enables more advanced athletes to examine performance analytics on a by-the-second level. With smart comparisons users can now benchmark their latest performance against their personal bests.
The new TomTom Sports app enables seamless data sharing with a range of third party platforms like Strava, Nike+, Endomondo, MapMyFitness, Runkeeper and many more.
Coming to your smartphone soon
The new TomTom Sports app will be available for download from the Apple Store and Google Play2 store starting at the end of January in most countries. The app works with iOS4 and Android3 smartphones and supports the TomTom Runner, TomTom Touch, TomTom Adventurer, TomTom Spark and TomTom Multi-Sport wearable ranges. For more information go to tomtom.com/sportsapp or watch our TomTom Sports App Product Video: https://youtu.be/KoJ5tyJsi7o
Visitors to CES can visit TomTom to find out more at: Sands Expo Hall C, Booth #43705 (level 2).
ENDS
The TomTom Sports app is compatible with the following devices:
Android: To ensure an excellent mobile experience, make sure to use the TomTom Sports App on phones with Bluetooth Smart (4.1 or higher) and Android version 4.4 or higher. The app needs to be connected to the internet to exchange information with your TomTom device. The following Android phones are supported:
• Samsung S7, S7 Edge, S6, S6 Edge, S5, S5 Mini, S5 Plus, S4, S4 Mini, A3, A5, Note 3, Note 4, J5
• Nexus 5, 5X, 6
• HTC One M8, M9
• LG G3, G4
• Sony Xperia Z3, Z3 Compact, Z5, Z5 Compact
• Huawei P8, P8 Lite
• OnePlus One
We will continue to add new phones to the list of supported Android devices in the future.
iOS: The TomTom Sports App only works on iPhone4 4S or higher and iOS8 or higher. The app needs to be connected to the internet to exchange information with your TomTom device.
About TomTom Sports
TomTom Sports is on a mission to help you get going.
Since 2009, we’ve developed Sports and Fitness products that make it easier to get moving.
We were the first to add an optical heart-rate monitor to a GPS Sports Watch with the TomTom Runner Cardio , and by integrating a music player into our Sports Watches we have enabled you to leave your smartphone at home. We’ve always been focused on innovating to make it easier to get going.
We also recently launched TomTom Touch , the first fitness tracker that combines body composition analysis with steps, sleep and all day heart-rate tracking, right from the wrist, technology usually reserved for elite athletes.
Find the full TomTom Sports product lineup here .
About TomTom
At TomTom (TOM2) our mission is to make technology so easy to use, that everyone can achieve more.
We created easy to use navigation devices, helping millions of people to get where they want to be. Today, we continue to simplify the complex, making technology more accessible for everyone.
We serve four different markets: Consumer, Telematics, Automotive and Licensing.
We make easy to use navigation devices, sport watches and action cameras for consumers. We enable businesses with vehicles to more easily manage and improve fleet efficiency whilst increasing overall business performance with our Telematics solutions. We also offer a world leading real-time map platform that is powering innovative location based services and helping to make automated driving a reality for the automotive industry.
Founded in 1991 and headquartered in Amsterdam, we have over 4,600 employees and sell our products worldwide.
1 Only with supporting TomTom devices
2 Google Play is a trademark of Google Inc.
3 Android is a trademark of Google Inc.4 iOS and iPhone are trademarks of Apple Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170105005171/en/
Contact:
For More Information:
Media
Rosanne van
Poelvoorde
+31 20 75 74 056
rosanne.vanpoelvoorde@tomtom.com
or
Investor
Relations
Bisera Grubesic
+31 20 75 75 194
ir@tomtom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom